Identifying biomarkers in adult Langerhans cell histiocytosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on adult Langerhans cell histiocytosis (LCH), a rare disease characterized by the activation of the MAPK pathway due to specific mutations. The study aims to assess the presence of MAPK mutations in plasma free cell DNA among patients with active systemic LCH and those with single system disease. By analyzing blood samples and biopsies, the research seeks to improve diagnostic and prognostic capabilities for LCH. The findings could lead to better understanding and management of this complex condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

LCH patients :

* Age ≥ 18 years
* All confirmed LCH seen at the reference center whatever the clinical presentation

Controls :

* Age ≥ 18 years
* Patients with diffuse lung cystic disease, pulmonary emphysema and healthy smokers

All :

* Signing an informed consent
* Patients with health insurance

Exclusion Criteria:

* Persons under guardianship or curatorship, or deprived of freedom by a judicial or administrative decision.
* People benefiting from Medical Aid from the State (AME)
* Pregnant women, parturient and mothers who are breastfeeding.
* Persons subject to psychiatric care and persons admitted to a health or social establishment for purposes other than research
* Persons unable to express their consent

Where it's running

• Hopital Saint Louis
  Paris, France Recruiting

Study contacts

• Study coordinator: Abdellatif Tazi, Pr
• Email: abdellatif.tazi@aphp.fr
• Phone: +33142499618

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• National registry study on adult pulmonary Langerhans cell histiocytosis

  This study looks at the long-term health and survival of adults with pulmonary Langerhans cell histiocytosis to see what factors might affect their outcomes.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT04665674

• Low-dose cytarabine combined with thalidomide for adults with newly diagnosed LCH

  This trial tests whether combining low-dose cytarabine with thalidomide is safe and effective for adults newly diagnosed with multisystem or multifocal Langerhans cell histiocytosis.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07187193

• Targeted treatment for Langerhans Cell Histiocytosis using trametinib

  This study is testing if trametinib, a new targeted therapy, can help children with Langerhans Cell Histiocytosis feel better and avoid the harsh side effects of traditional chemotherapy.

  Recruiting Phase 2 Cook Children's Health Care System · Fort Worth, Texas · NCT06582745

• Evaluating FCN-159 for treating pediatric patients with recurrent LCH

  This study is testing a new medication called FCN-159 to see if it can help children aged 2 to 16 with recurring Langerhans cell histiocytosis feel better.

  Recruiting at 2 sites Phase 2 Fosunpharma · Beijing, Beijing Municipality and 10 other locations · NCT05997602

• Follow-up on health outcomes in patients with histiocytic disorders

  This study looks at the long-term health effects of histiocytic disorders on around 6000 patients to see how these conditions impact their overall well-being and quality of life.

  Recruiting University of Alabama at Birmingham · Birmingham, Alabama · NCT05915208

• Using cobimetinib to treat refractory Langerhans cell histiocytosis and other histiocytic disorders

  This study is testing if a drug called cobimetinib can help people with hard-to-treat Langerhans cell histiocytosis and other similar disorders feel better.

  Recruiting at 10 sites Phase 2 Baylor College of Medicine · Phoenix, Arizona and 11 other locations · NCT04079179

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.